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BACKGROUND AND PURPOSE
Mitochondria are a drug target in mitochondrial dysfunction diseases and in antiparasitic chemotherapy. While zebrafish is
increasingly used as a biomedical model, its potential for mitochondrial research remains relatively unexplored. Here, we
perform the first systematic analysis of how mitochondrial respiratory chain inhibitors affect zebrafish development and
cardiovascular function, and assess multiple quinones, including ubiquinone mimetics idebenone and decylubiquinone, and
the antimalarial atovaquone.
EXPERIMENTAL APPROACH
Zebrafish (Danio rerio) embryos were chronically and acutely exposed to mitochondrial inhibitors and quinone analogues.
Concentration-response curves, developmental and cardiovascular phenotyping were performed together with sequence
analysis of inhibitor-binding mitochondrial subunits in zebrafish versus mouse, human and parasites. Phenotype rescuing was
assessed in co-exposure assays.
KEY RESULTS
Complex I and II inhibitors induced developmental abnormalities, but their submaximal toxicity was not additive, suggesting
active alternative pathways for complex III feeding. Complex III inhibitors evoked a direct normal-to-dead transition. ATP
synthase inhibition arrested gastrulation. Menadione induced hypochromic anaemia when transiently present following
primitive erythropoiesis. Atovaquone was over 1000-fold less lethal in zebrafish than reported for Plasmodium falciparum, and
its toxicity partly rescued by the ubiquinone precursor 4-hydroxybenzoate. Idebenone and decylubiquinone delayed rotenone-
but not myxothiazol- or antimycin-evoked cardiac dysfunction.
CONCLUSION AND IMPLICATIONS
This study characterizes pharmacologically induced mitochondrial dysfunction phenotypes in zebrafish, laying the foundation
for comparison with future studies addressing mitochondrial dysfunction in this model organism. It has relevant implications
for interpreting zebrafish disease models linked to complex I/II inhibition. Further, it evidences zebrafish’s potential for in vivo
efficacy or toxicity screening of ubiquinone analogues or antiparasitic mitochondria-targeted drugs.
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Abbreviations
3NP, 3-nitropropionic acid; 4HB, 4-hydroxybenzoic acid; 4NB, 4-nitrobenzoic acid; ATV, atovaquone; bpm, beats
per minute; COX, cytochrome c oxidase; DCB, decylubiquinone; DCM, dicoumarol; DHODH, dihydroorotate
dehydrogenase; DPR, diospyrin; DQN, diosquinone; ETFDH, electron transfer flavoprotein dehydrogenase; hpf, hours
post fertilization; IDB, idebenone; JGL, juglone; LPC, lapachol; mDNA, mitochondrial DNA; MND, menadione; ND1,
NADH dehydrogenase subunit 1; NQO1, NAD(P)H:quinone oxidoreductase; NTZ, naphthazarin; PLB, plumbagin; ROS,
reactive oxygen species; VPA, valproic acid; bLPC, b-lapachone
Introduction
Mitochondrial dysfunction is a common feature in multiple
human diseases. Mitochondrial diseases present diverse clini-
cal symptoms with the most common being neurological
and cardiological manifestations, including cardiomyopa-
thies and heart conduction defects (Tuppen et al., 2010;
Berardo et al., 2011). Mutations in mitochondrial DNA
(mDNA) may affect respiratory chain elements or ribosomal
and transfer RNAs required for mitochondrial gene expres-
sion, causing diseases such as Leber’s hereditary optic neu-
ropathy or mitochondrial myopathy, encephalopathy, lactic
acidosis and stroke syndrome (Tuppen et al., 2010). Also,
mutations in nuclear encoded mitochondrial proteins
are associated with human diseases (e.g. optic atrophy or
Charcot-Marie-Tooth 2A). Furthermore, key neurodegenera-
tive disorders such as Alzheimer, Parkinson and Huntington
diseases, among others, have been associated with mitochon-
drial dysfunction (Oliveira, 2010). Current treatment options
for mitochondrial dysfunction disorders are scarce and mostly
symptomatic (Finsterer, 2010). Further treatment develop-
ment is partly hindered by limited in vivo models of mito-
chondrial disease. Notably, strong purifying selection in the
mammalian female germ line imposes difficulties in establish-
ing mouse models of mDNA mutations (Stewart et al., 2008).
Zebrafish (Danio rerio) is increasingly used for modelling
human diseases (Ingham, 2009). Its mitochondrial genome is
sequenced (Broughton et al., 2001) and zebrafish is emerging
as a model for studying mitochondria-linked disorders.
Indeed, silencing mitofusin-2 in zebrafish generated an in vivo
model of Charcot-Marie-Tooth 2A neuropathy (Vettori et al.,
2011). Similarly, depletion of cytochrome c oxidase (COX),
optic atrophy 3 protein and electron transfer flavoprotein
dehydrogenase (ETFDH) were respectively used to model
COX deficiency (Baden et al., 2007), Costeff syndrome (Pei
et al., 2010) and multiple acyl-CoA dehydrogenase deficiency
in zebrafish (Song et al., 2009). Moreover, zebrafish was
reported sensitive to mitochondrial toxins linked to Parkin-
son’s disease (Bretaud et al., 2004), and parkin knockdown
in embryos led to mitochondrial complex I deficiency
(Flinn et al., 2009). Currently, few studies addressed normal
zebrafish mitochondrial physiology and bioenergetics. These
include analysis of mDNA metabolism (Artuso et al., 2012),
oxygen consumption (Stackley et al., 2011), calcium buffer-
ing and mitochondrial permeability transition (Azzolin et al.,
2010) in zebrafish embryos. Still, further studies are required
to validate zebrafish as a model to study mitochondrial
dysfunction and its experimental treatment, including the
identification of similarities and specific limitations when
extrapolating towards mammalian physiology.
Here, we model mitochondrial dysfunction in zebrafish
and use it to test mitochondria-targeted drugs. We character-
ize the effects of mitochondrial inhibitors and quinone
analogues on zebrafish embryonic development and cardio-
vascular function, identifying morphological and functional
phenotypes associated with impaired respiratory complexes
and ubiquinone deficiency. Among several quinone ana-
logues, we test the ubiquinone mimetics idebenone and decy-
lubiquinone. Also, we test the antimalarial atovaquone,
appraising zebrafish’s potential for differential toxicity
screening of the growing class of mitochondria-targeted
antiparasitic drugs (Mather et al., 2007).
Methods
Drugs, solvents and solutions
Mitochondrial inhibitors [rotenone, 3-nitropropionic acid
(3NP), myxothiazol, antimycin and oligomycin] and all other
drugs/chemicals were from Sigma-Aldrich (St. Louis, MO,
USA), unless otherwise stated. Quinones analogues were:
natural monomeric naphthoquinones [menadione (MND),
juglone (JGL), naphthazarin (NTZ), plumbagin (PLB), lapa-
chol (LPC) and b-lapachone (bLPC)]; natural dimeric naphtho-
quinones [diospyrin (DPR) and diosquinone (DQN)]; synthetic
naphthoquinone [atovaquone (ATV)]; and synthetic benzo-
quinones [idebenone (IDB) and decylubiquinone (DCB)].
Other drugs include the ubiquinone synthesis precursor
[4-hydroxybenzoic acid (4HB)] and respective inhibitor
[4-nitrobenzoic acid (4NB)]; the NAD(P)H:quinone oxidore-
ductase (NQO1) inhibitor [dicoumarol (DCM)]; and the
control abnormality inducer [valproic acid (VPA)]. DPR and
DQN were isolated from root barks of Diospyros chamaetham-
nus Dinter ex Mildbr (Costa et al., 1998). 4HB was from Extra-
synthese (Genay Cedex, France). For all drugs, chemical
structures are in Supporting Information Figure S1, summa-
rized data in Table 2 and Figure 5C, and their mechanism/
sites of action depicted in Figure 8. Stock drug solutions were
prepared in water, DMSO or methanol, according to their
solubility. Prior to assays, stocks were diluted in dechlorin-
ated autoclaved water (egg water). Non-water drug solvents,
DMSO or methanol, were kept constant at all drug dilutions
and always below 0.5 or 0.05% respectively. These solvent
concentrations induced no significant effects (Figure 1B).
Egg production
Adult wild-type zebrafish (Da. rerio), were maintained at 28 
1°C on a 14 h:10 h light:dark cycle, and handled for egg
production as we previously detailed (Soares et al., 2009).
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Briefly, adults (14:7 male:female) were placed in a 30 L breed-
ing tank on the day before egg collection. Ninety minutes
after starting the light period, eggs were collected and
cleaned. This time point was recorded as 0 h post fertilization
(hours per fertilization, hpf; Figure 1A).
Chronic drug exposure assays
Embryo maintenance and drug treatment. Embryos were ran-
domly distributed in 12-well plates (10 embryos/well; 2 mL
egg water/well) and kept at 28 1°C on a 14 h:10 h light:dark
cycle throughout the assay. Embryos were continuously
exposed to drugs from 4 to 80 hpf. VPA, a known teratogen in
zebrafish, was used as positive control for developmental
abnormalities and also cardiovascular abnormalities such
as bradycardia (Gurvich et al., 2005). Dead embryos were
removed during the readings (Figure 1A) and two out of three
of each well content was renewed with freshly prepared drug
solution at 32 and 56 hpf. All drug concentrations were
assayed in duplicate wells (10 + 10 eggs), in at least three
independent experiments (60 eggs).
Monitoring of zebrafish development and cardiac function. At
regular time points (8, 32, 56 and 80 hpf: Figure 1A) em-
bryos were scored as normal, abnormal or dead; hached/
unhatched; using a stereomicroscope (Stemi DV4, Zeiss, Göt-
tinger, Germany) or an inverted microscope (Eclipse TS 100,
Nikon, Tokyo, Japan) with colour camera (Nikon 8400;
Tokyo, Japan) for digital recording. Normal development was as
previously described (Kimmel et al., 1995). Abnormalities were
organized as: pigmentation, cardiac and structural – for
subdivisions description and photographs see Table 1 and
Figure 2A. Heart rates (Figure 5A) were measured in two
embryos per phenotype per well, during 20 s, at 80 hpf.
Weighted averages (Figure 5Ai) consider the embryos with/
without cardiac oedema among the live population per well.
For detailed heartbeat analyses (Figure 5B), videos were
recorded at 20¥ magnification in an inverted microscope
Figure 1
Mitochondrial inhibitors and zebrafish development. A, Protocol and images of normal development. B–G, Changes in normal (white circles),
abnormal (grey triangles), dead (black circles) and hatched (white diamonds) embryos (% total) across time and drug concentrations. B, Controls
– egg water (i), with 0.5% DMSO (ii) and 0.05% methanol (iii, MeOH). C–G, Mitochondrial inhibitors. Data are mean  SEM of n independent
experiments: control: n = 34, 4 and 4, for egg water, DMSO and MeOH, respectively; rotenone, n = 4–14; 3NP, n = 3–9; myxothiazol, n = 4–12;
antimycin, n = 5–6; oligomycin, n = 3–5. C-Giii, Arrows – peak abnormalities at 80 hpf.
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(Eclipse TE300, Nikon), with CCD camera (C6790; Hama-
matsu Photonics, Hamamatsu, Japan) and Aquacosmos soft-
ware (version 2.5; Hamamatsu Photonics). Videos were
captured at 28 Hz during 10 s and processed with ImageJ
(NIH) for assessing atrioventricular coordination.
Parameters and abnormality indexes. NC50, AC25 and LC50
signify concentrations required for, respectively, 50%
decrease in normal embryos, 25% of embryos with abnor-
malities and 50% lethality. LS and NS are slopes from
concentration-response curves depicting dead and normal
embryos respectively. Abnormality indexes were expressed by
LC50/NC50 and LS/-NS ratios. Both are ~1 when increasing
drug concentrations convert normal embryos directly into
dead embryos. When abnormal embryos survive, the LC50/
NC50 ratio is >1. The LS/-NS can still be ~1, but otherwise is
inversely proportional to the resilience of abnormal embryos
to increasing drug concentrations. Indeed, an LS steeper or
shallower than -NS signifies a more or less abrupt abnormal-
to-dead conversion respectively.
Acute drug exposure assays. Hatched embryos at 56 hpf were
randomly distributed in 12-well plates (10 embryos in 2 mL
egg water/well). Following acute exposure to isolated or
combined drugs, embryos were scored for presence/absence
of circulation and heartbeat at 10 min intervals. For each
treatment, 40–60 embryos, from two to three independent
clutches, were assayed in two to three independent
experiments, before data aggregation for Kaplan–Meier
analysis.
Data sources and comparison of protein sequences. Protein
sequence data of NADH dehydrogenase subunit 1 (ND1,
complex I), succinate dehydrogenase complex subunit A
(complex II), cytochrome b (complex III) and ATPase subunit
6 and 9 (complex V) were obtained from NCBI (http://
ncbi.nlm.nih.gov/protein). Percentages of identity were cal-
culated using BLAST (http://blast.ncbi.nlm.nih.gov/Blast.
cgi). COBALT (http://www.ncbi.nlm.nih.gov/tools/cobalt)
was used to align cytochrome b sequences (Figure 3).
Statistics. Values are mean  SEM from n independent
experiment, unless otherwise stated. Conventional ‘E nota-
tion’ is used when appropriate. For normally distributed
data, t-test or ANOVA were used, respectively, to compare
two or more groups. The Mann–Whitney test and Kruskal–
Wallis ANOVA were used for non-normally distributed
data. Changes in proportion of embryos with/without cir-
culation or heartbeat were analysed via Kaplan–Meier.
Cluster analysis was performed by k-means clustering, pre-
ceded by exploratory hierarchical clustering. Linear regres-
sions (for computing NC50, AC25, LC50, and slopes – NS, LS)
and non-parametric tests were performed with GraphPad
Prism version 5.0 (San Diego, CA, USA). All other statistical
analyses were performed with SPSS 20.0 (SPSS Inc., Chicago,
IL, USA). Differences from control were considered statisti-
cally significant when P < 0.05. Simultaneous biological
relevance was assumed only for differences larger than 10%
(D > 10%).Ta
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Results
Mitochondrial inhibitors induce different
abnormalities in zebrafish
To assess how mitochondrial dysfunction affects zebrafish
development, fertilized eggs were chronically exposed to dif-
ferent mitochondrial inhibitors. Protocol and concentration-
response curves are in Figure 1 and representative
abnormalities (Figure 2A) described in Table 1.
Complex I and II inhibitors (rotenone and 3NP, respec-
tively) induced more abnormalities in surviving embryos
than complex III inhibitors (myxothiazol and antimycin),
which primarily induced a direct transition from normal to
dead. The ATP synthase inhibitor (oligomycin) arrested sur-
viving embryos at the gastrula stage, followed by a time-
dependent death (Figure 1C-G and Figure 2B-G). The order of
potency for lethality was antimycin > myxothiazol > roten-
one > oligomycin > 3NP (LC50 in Table 2). Comparing LC50/
NC50 and LS/-NS ratios at 80 hpf (Table 2) highlights 3NP as
the most frequent inducer of abnormalities among the mito-
chondrial inhibitors (highest LC50/NC50 and lowest LS/-NS;
AC25 = 3.4E3  1.7E2mM, n = 4), followed by rotenone, myxo-
thiazol, antimycin and oligomycin. At 56 hpf, oligomycin
stands out as an abnormality inducer, but the corresponding
embryos do not survive until 80 hpf (Table 2, Figure 2G).
Types and frequency of abnormalities varied across
mitochondrial inhibitors (Figure 2B-G). Rotenone and 3NP
significantly decreased pigmentation (melanin) at 56 hpf sug-
gesting developmental delay, and induced cardiovascular
abnormalities (oedema and asystole); 3NP also caused
necrotic lesions and head abnormalities (abnormal otoliths);
Figure 2C,D. Oligomycin-induced abnormalities were prima-
rily arrests at the gastrula stage, lethal at 80 hpf (Figure 2G).
Figure 2
Mitochondrial inhibitors and abnormalities in zebrafish. A, Representative abnormalities in comparison with post- and pre-hatched control
embryos (top and bottom left, respectively) at 80 hpf. B, Spontaneous abnormalities under control conditions; C–G, Mitochondrial inhibitor
induced abnormalities at the indicated concentrations (arrows in Figure 1C-Giii); Boxplots (specific abnormalities, % total embryos) show median,
mean (+), interquartile distances, maximum and minimum; Symbols (normal, white circles; abnormal, grey triangles; and dead; black circles) show
mean  SEM (% total, embryos). Data are from n independent experiments: control: n = 34; rotenone (RTN), n = 14; 3-nitropropionic acid (3NP),
n = 9; myxothiazol (MYX), n = 12; antimycin (ANT), n = 5; oligomycin (OLG), n = 5. *P < 0.05 in boxplots, Kruskal–Wallis ANOVA with Dunn’s post
hoc (vs. control). *P < 0.05 in grey triangles (mean abnormalities), One-way ANOVA with Bonferroni post hoc (vs. control).
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Myxothiazol and antimycin evoked no statistically signifi-
cant abnormalities (Figure 2E,F), consistent with direct tran-
sition from normal to dead (Figure 1E,F).
Heart rate analysis showed that bradycardia and cardiac
oedema were strongly associated (Figure 5Aii vs. Aiii; with
few exceptions). Control heart rate was 179  3 beats per
minute (bpm) and 163  5 bpm, for embryos without
and with spontaneous oedema respectively (Figure 5Aiii).
Embryos with oedema caused by rotenone, 3NP, myxothiazol
or oligomycin, all displayed concentration-dependent brady-
cardia, more pronounced than that caused by spontaneous
oedema in controls (Figure 5Aiii). In weighted average,
however, only 3NP caused relevant bradycardia among the
mitochondrial inhibitors (Figure 5Ai), consistent with its
higher proportion of oedema (Figure 2Diii). Also, cluster
analysis and scaling across three domains (cardiac, structural
and pigmentation) clearly separated 3NP from all other mito-
chondrial inhibitors (Cluster 5; Figure 5C).
Comparison of mitochondrial complex
subunits between zebrafish, human,
mouse and parasites targetable with
quinone analogues
To appraise zebrafish for mitochondrial dysfunction model-
ling and drug testing, we compared inhibitor-binding subu-
nits for rotenone (Earley et al., 1987), 3NP (Huang et al.,
2006), myxothiazol, antimycin, atovaquone (Mather et al.,
2007) and oligomycin (Devenish et al., 2000) – (Figure 3A,B).
Pneumocystis jiroveci (Hughes et al., 1990) and Plasmodium
falciparum (Fry and Pudney, 1992) are included because of
relevant cytochrome b differences allowing selective targeting
with atovaquone (Fry and Pudney, 1992; Mather et al., 2007).
Zebrafish identity with human subunits is only 9–13% lower
than mouse versus human, except for ATPase subunit 6
(Figure 3A). Our LC50 for mitochondrial inhibitors in
zebrafish were lower than LC50 or concentrations fully inhib-
iting mammalian mitochondrial complexes, except 3NP
where only its AC25 approximated the LC50 reported for mam-
malian cells (Table 2). The genetic and functional correlation
is evidenced by ND1 and complex V subunit 6 absence in
Pl. falciparum versus zebrafish/mammals, and the associated
10-fold higher concentrations required for rotenone or
oligomycin to kill Pl. falciparum versus zebrafish embryos
in this study (Table 2). Differences in cytochrome b Qo
(binds myxothiazol/atovaquone) and Qi (binds antimycin)
(Figure 3B) are functionally relevant since antimycin displays
>1000-fold lower LC50 towards zebrafish/mammals versus
parasites. Therapeutically more relevant, atovaquone displays
much higher toxicity towards Pl. falciparum versus zebrafish/
mammals (Table 2).
Quinone analogues and other
ubiquinone-related compounds induce
different abnormalities in zebrafish
Aiming to validate zebrafish as in vivo model for exploring the
therapeutic potential of quinone analogues, we tested their
Figure 3
Amino acid sequence comparison of mitochondrial inhibitor-binding subunits. A, Percentage of identity among inhibitor-binding subunits of
mitochondrial complexes I, II, III and V (NADH dehydrogenase subunit 1, ND1; succinate dehydrogenase subunit A, cytochrome b, and ATPase
subunits 6 and 9), from human, mouse, zebrafish and parasites targetable with quinone analogues (P. jiroveci and P. falciparum; ‘n.a.’, not
applicable – no homologue subunit in this species). B, Comparison of Qo and Qi sites (grey highlight). Xn summarises non-Qo/Qi amino acids.
BJPZebrafish mitochondria and quinone drugs
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effects in chronically (4–80 hpf) exposed embryos, along with
other drugs for mechanistic studies (Supporting Information
Figure S1). All 11 quinone analogues were lethal within the
tested range of concentrations (Table 2). The LC50 interval
0.5–1 mM includes PLB, DQN and JGL; 1–10 mM includes ATV,
bLPC, DPR, MND, NTZ, IDB and LPC. The least lethal of all
quinone analogues was decylubiquinone (DCB; LC50 at 80 hpf
= 20.10  0.74 mM, n = 3). Other drugs exhibited an LC50
comprised between 21 mM and 4 mM (DCM, VPA and 4NB);
The LC50 for 4HB was >5 mM, its AC25 at 80 hpf was 1.3 
0.66 mM, n = 5. Relatively few (4:11) quinone analogues
induced a significant proportion of structural/functional
abnormalities (ATV, LPC, MND and DCB; Table 2, LC50/
NC50>1; Figure 4). Among the ‘other drugs’, 4NB, DCM and
VPA exhibited an LC50/NC50>1 at either 56 or 80 hpf (Table 2
and Figure 4).
Atovaquone induced abnormalities were primarily
cardiac oedema and focal lesions (e.g. bleedings/clots), most
noticeable at 1 mM and 56 hpf (some lethal at 80 hpf;
Figure 4A). Meaningfully, although atovaquone shares
complex III inhibition with myxothiazol and antimycin
(Figure 8A), it induces different abnormalities (Figure 2E,F vs.
Figure 4A), which may be better explained by atovaquone’s
inhibition of ubiquinone synthesis (Figure 8D). Consistently,
the ubiquinone synthesis inhibitor 4NB replicated distin-
guishing atovaquone features, such as focal lesions and pro-
nounced cardiac oedema without relevant bradycardia
(Figure 4A vs. Figure 4D; Figure 5Aiii).
Decylubiquinone’s lethality was strikingly time-
dependent increasing about 90% from 56 to 80 hpf
(Figure 4B). Decylubiquinone caused a tail fin anomaly
(Figure 2A; ~50% embryos at 10 mM; Figure 4Eiv, 80 hpf), also
observed within 90 min of exposure in hatched embryos
(experiments in Figure 7A), suggesting altered neuromuscular
tonus and not necessarily developmental defects. Interest-
ingly, the structurally related idebenone (terminal –OH in
decylubiquinone’s aliphatic chain; Supporting Information
Figure 1) displayed higher lethality (~3¥ lower LC50; Table 2)
and no significant abnormalities other than delayed pigmen-
tation (melanin; Figure 4C).
Lapachol (10 mM) induced a diverse abnormality profile
afflicting ~80% embryos at 56 hpf, precluding hatching and
leading to >50% death at 80 hpf (Figure 4Fi,iii). Lapachol
caused decreased pigmentation (melanin), head defects
(abnormal eyes, otoliths and craniofacial defects), gastrula
arrest, oedema and asystole (Figure 4Fii,iv). Asystole was
typically preceded by cardiac oedema and concentration-
dependent bradycardia (Figure 5A; with signs of atrioven-
tricular block Figure 5Biii). In contrast, dicoumarol (50 mM)
abnormalities were merely decreased melanin (Figure 4G).
Menadione (1 mM) was the single most powerful inducer
of hypochromic anaemia among 20 compounds, affecting
the majority of embryos at 80 hpf (Figure 4H). We thus inves-
tigated hypochromic anaemia, modulating the duration and
developmental stage of menadione exposure. Strikingly, a
short exposure from 24 to 32 hpf sufficed to evoke over 50%
hypochromic anaemia at 80 hpf, whereas longer exposures at
earlier (8–24 hpf) or later (48-80 hpf) stages resulted in nor-
mally coloured erythrocytes at 80 hpf (Figure 4 K).
Rescue experiments with ubiquinone
analogues or precursor during chronic
mitochondrial inhibition
Idebenone and decylubiquinone fail to rescue chronic mitochon-
drial inhibition. Following individual drug titration, we
tested whether ubiquinone analogues rescued the effects of
chronic mitochondrial inhibition in zebrafish. Embryos were
chronically exposed to concentrations inducing the highest
percentage of abnormalities at 80 hpf for rotenone (0.1 mM),
3NP (10 mM), myxothiazol (0.03 mM) and atovaquone
(1 mM), in the presence or absence of the highest concentra-
tion of ubiquinone analogues without detectable chronic
toxicity (1 mM idebenone; 3 mM decylubiquinone). Neither
idebenone nor decylubiquinone rescued changes in number
of normal embryos, hatching, heart rate or oedema induced
by chronic mitochondrial inhibition (Figure 6A).
Zebrafish has active alternative ubiquinone reduction path-
ways. Lack of rescuing from chronic complex I or II inhibi-
tion with ubiquinone analogues prompted us to test whether
combined rotenone and 3NP displayed additive toxicity.
Results showed that the combination of rotenone (0.1 mM)
with 3NP (10 mM) does not exceed the toxicity of 3NP alone
(Figure 6C). Together with development beyond the gastrula
stage requiring mitochondrial ATP synthesis (oligomycin
effect; Figure 2G), these results suggest that alternative
ubiquinone reduction pathways actively feed complex III
(Figure 8C), supporting mitochondrial ATP synthesis.
Given the possible contribution of NQO1 in the reduction
of idebenone to idebenol and feeding of complex III [(Haefeli
et al., 2011); Figure 8D], we appraised the contribution of this
enzyme by testing how its inhibitor dicoumarol modulated
toxicity of its substrates – menadione and b-lapachone.
Results showed that dicoumarol (50 or 500 nM; concentra-
tions devoid of lethality, Figure 4G) did not significantly

Figure 4
Influence of quinone analogues and ubiquinone related compounds on zebrafish development. A-I, i, iii, Mean  SEM of changes in normal,
abnormal, dead and hatched embryos (% total) for the indicated times (56 and 80 hpf) and drug concentrations; ii, iv, Boxplots (specific
abnormalities, % total embryos) show median, mean (+), interquartile distances, maximum and minimum, for the indicated concentrations
(arrow; peak abnormalities at 80 hpf). Data are from n independent experiments with: A, atovaquone, n = 3–12; B, decylubiquinone, n = 4–8 C,
idebenone, n = 3–8; D, 4NB, n = 3–11; E, 4HB, n = 4–16; F, lapachol, n = 3–5; G, dicoumarol, n = 3–8; H, menadione, n = 3–15; and I, b-lapachone,
n = 3–10. *P < 0.05, Mann–Whitney (vs. control) if difference in medians >10%. J, Effect of dicoumarol [DCM; NQO1 inhibitor, (Preusch et al.,
1991)] upon abnormalities induced by menadione (MND) or b-lapachone (bLPC) at 80 hpf. P > 0.05 for differences between MND/bLPC alone
versus combined with 50 or 500 nM DCM, one-way ANOVA with Bonferroni post hoc, n = 5–6. K, Periods of menadione (1 mM) exposure and
resulting mean  SEM of embryos with hypochromic anaemia (% live, 80 hpf). *P < 0.05 versus 48–80hpf exposure, ANOVA with Bonferroni post
hoc, n = 3–4 independent experiments. The periods of primitive, transient and definitive haematopoiesis were derived from (Chen and Zon, 2009).
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increase the toxicity of 1 mM menadione [predicted to be
detoxified by NQO1; (Kishi et al., 2002)] and did not decrease
the toxicity of 3 mM b-lapachone [predicted to be bioactivated
by NQO1; (Li et al., 2011)] (Figure 4J, Figure 8D).
The ubiquinone precursor 4HB rescues atovaquone but not myxo-
thiazol or antimycin toxicity. Given the central role of ubiq-
uinone and complex III in energizing the mitochondrial
respiratory chain, we tested whether the ubiquinone precur-
sor 4HB (5 mM) could rescue the toxicity of complex III
inhibitors (Figure 6B). Although failing to rescue embryos
from myxothiazol or antimycin toxicity, 4HB significantly
rescued atovaquone toxicity, increasing the proportion of
normal embryos (Figure 6Bi; P < 0.05, D > 10%) and display-
ing a trend towards decreased oedema (Figure 6Biii; ATV vs.
ATV+4HB). 4HB failed to rescue the effects of the ubiquinone
synthesis inhibitor 4NB (Figure 6B). The 2000-fold difference
in concentrations required for 4NB toxicity (10 mM;
Figure 4D) vs. 4HB efficacy (5 mM; Figure 6B), and the toxicity
displayed by 5 mM 4HB (Figure 4E) precluded equimolar
competition in rescue assays with 4HB and 4NB.
Rescue experiments with
ubiquinone analogues upon acute
mitochondrial inhibition
Acute complex I inhibition with rotenone induces cardiac insuffi-
ciency and asystole via ATP depletion. Following literature
data supporting in vitro rescuing by ubiquinone analogues of
decreased mitochondrial oxygen consumption or ATP levels
in synaptosomes (Telford et al., 2010), cell lines (Haefeli et al.,
2011) or isolated mitochondria (James et al., 2005), we aimed
to establish an in vivo testing paradigm for ubiquinone ana-
logues in zebrafish. Thus, we monitored circulation and
heartbeat in 56 hpf embryos acutely challenged with mito-
chondrial inhibitors with or without ubiquinone analogues
(idebenone or decylubiquinone; Figure 7). Circulatory arrest
Figure 5
Detailed heartbeat analysis and multiple-abnormalities profiling. A, Concentration-dependent changes in heart rate at 80hpf, showing total
weighted average (i, see Methods), and separating embryos without (ii) from those with (iii) cardiac oedema; embryos in asystole were excluded
from calculations. Horizontal rectangles are the 95% confidence interval (CI) for control means without (light grey) and with (dark grey, iii)
spontaneous cardiac oedema, n = 33 experiments. Data for drugs are mean  SEM from n = 3–14 experiments. B, Detailed heartbeat analysis at
56 hpf showing examples of normal atrioventricular coordination and frequency (i), bradicardia (ii), atrioventricular block (iii) and supraventricular
arrhythmia (iv). C, Multi-dimensional scaling and clustering of abnormality profiles at 80 hpf. Axes are the sum of mean abnormalities for the
respective subdomains (Table 1). Clusters: 1 (3NP); 2 (DCB); 3 (MND and 4HB); 4 (VPA, LPC and 4NB); 5 (all other drugs); k-means clustering.
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Figure 6
Effect of ubiquinone analogues and precursor upon chronic mitochondrial inhibition. A,B, Normal embryos (i), hatching (ii), and average heart
rate (iii; asystole included) in % of control, as well as oedema in surviving embryos (% live; iii); Readings at 80 hpf, following chronic exposure
to the indicated concentrations of drugs isolated vs. combined with idebenone (IDB, 1 mM, A) or decylubiquinone (DCB, 3 mM, A), or with
4-hydroxybenzoate (4HB, 5 mM, B). Data are mean  SEM on n independent experiments with rotenone (RTN, 0.1 mM, n = 4), 3-nitropropionic
acid (3NP, 10 mM, n = 3), myxothiazol (MYX, 0.03 mM, n = 5; 0.1 mM, n = 6), atovaquone (ATV, 1 mM; n = 6, A; n = 6, B), antimycin (ANT, 3 nM,
n = 3), and 4-nitrobenzoate (4NB, 10 mM, n = 4). *P < 0.05 for combined vs. isolated drug, unpaired t-test. C, Normal, abnormal and dead
embryos upon chronic exposure to 3NP (10 mM), alone or combined with RTN (0.1 mM). Data are mean  SEM for n = 3 independent
experiments, with readings at 32 (i), 56 (ii) and 80 hpf (iii). Note that 3NP toxicity (judged from abnormal and dead embryos vs. normal) does
not increase upon combination with rotenone.
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Figure 7
Effect of ubiquinone analogues upon acute mitochondrial inhibition. A,B, Time-dependent changes in proportion of 56 hpf zebrafish with active
circulation (i,ii) and heartbeat (iii,iv) following acute exposure to mitochondrial inhibitors (at time = 0 min). Ai,iii, Rotenone (RTN, 1 mM)
with/without idebenone (IDB, 3 mM) or decylubiquinone (DCB, 30 mM); Aii,iv, RTN (1 mM) and oligomycin (OLG, 3 mM), alone and combined.
Bi-iv, Myxothiazol (MYX, 1 mM) or antimycin (ANT, 0.1 mM), with/without IDB (3 mM) or DCB (30 mM). *P < 0.05 and % delay in circulatory arrest
or assystole; Kaplan-Meier with Log Rank. Data are from 40–60 embryos per treatment, from 2–3 independent clutches. IDB or DCB (IDB/DCB)
alone maintained 100% circulation or heartbeat throughout the experiment.
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upon acute mitochondrial inhibition was associated with
bradycardia and atrioventricular block (e.g. Figure 5Biii) or
supraventricular arrhythmia (e.g. Figure 5Biv), and followed
by asystole. Mitochondrial ATPase inhibition (oligomycin)
evoked circulatory arrest. When combined, oligomycin did
not modify rotenone’s circulatory arrest (Figure 7Aii), but
delayed rotenone induced asystole by 18% (Figure 7Aiv,
P < 0.05). The latter can be explained by preventing ATP
consumption upon rotenone induced ATPase reversal.
Idebenone and decylubiquinone delay the onset of cardiac dysfunc-
tion evoked by rotenone but not by myxothiazol or antimycin.
Idebenone (3 mM) and decylubiquinone (30 mM) delayed
rotenone induced cardiac insufficiency, respectively, by 61
and 79% (Figure 7Ai, P < 0.05), and also delayed asystole,
respectively by 52 and 104% (Figure 7Aiii, P < 0.05). In con-
trast, both ubiquinone analogues failed to protect from
cardiac dysfunction induced by either myxothiazol (1 mM;
Figure 7Bi,iii) or antimycin (100nM, Figure 7Bii,iv).
Discussion and conclusions
Modelling mitochondrial dysfunction
in zebrafish
Mitochondrial respiratory chain and inhibitors. Here, we show
that zebrafish and mammalian mitochondria display high
genetic and functional homology, and characterize the devel-
opmental and cardiovascular consequences of mitochondrial
dysfunction evoked by respiratory chain inhibitors. Chronic
complex I or II inhibition induced developmental abnormali-
ties, whereas complex III inhibition directly converted
normal into dead embryos, plausibly by lack of downstream
alternatives to sustain mitochondrial ATP synthesis. Interest-
ingly, when combining effective concentrations of rotenone
and 3NP, lack of additive effects suggests a negligible residual
complex I activity during complex II inhibition and vice versa.
Yet, albeit abnormal, embryos undergo organogenesis and
survive past 80 hpf. Because this cannot happen without
mitochondrial ATP synthesis (oligomycin arrests gastrula-
tion), data suggests alternative mitochondrial dehydroge-
nases [ETFDH, glycerol-3-phosphate dehydrogenase or
dihydroorotate dehydrogenase (DHODH); Figure 8] actively
reduce endogenous ubiquinone to support mitochondrial
ATP production. This is important for interpreting zebrafish
models of complex I or II deficiencies, for example in primary
mitochondrial disease or in neurodegenerative disorders
which have been associated with deficits in complexes I or II,
such as Parkinson and Huntington’s diseases respectively.
Specifically, alternative feeding of complex III may explain
why parkin knockout zebrafish presented 45% reduction of
complex I activity without significant changes in swimming
behaviour (Flinn et al., 2009).
While the concentrations we have used for mitochondrial
inhibitors are within the range commonly used in the litera-
ture, it is conceivable that in zebrafish, as with other models,
there may be some contribution of off-target effects, such
as microtubule depolymerization by rotenone (Choi et al.,
2011), and fumarase inhibition by 3NP (Porter and Bright,
1980).
Cytosolic dehydrogenase: NQO1. In contrast with mito-
chondrial dehydrogenases, cytosolic NQO1 unlikely feeds
complex III physiologically, since ubiquinone hydrophobic-
ity precludes significant cytosolic-mitochondria shuttling.
Pharmacologically, however, NQO1 may be quite relevant in
reducing exogenous ubiquinone analogues (Haefeli et al.,
2011; Giorgio et al., 2012). Indeed, exogenous idebenone or
decylubiquinone must travel the cytosol, where they may be
reduced by NQO1, before feeding electrons to mitochondrial
complex III. NQO1 inhibition was reported to decrease mela-
nogenesis in zebrafish and melanoma cell lines (Choi et al.,
2010). Here, we tested the NQO1 inhibitors dicoumarol and
lapachol and both caused melanin defects in zebrafish
embryos. Interestingly, lapachol was more potent than dicou-
marol for melanin defects and presented a wider spectrum
of abnormalities. Considering the higher NQO1 inhibiting
potency of dicoumarol versus lapachol [IC50 = 10nM vs.
150nM, respectively; (Preusch, 1986; Preusch et al., 1991)],
we argue that effects may instead be mediated by DHODH
inhibition, where lapachol was shown more potent than
dicoumarol [IC50 = 61nM vs. 5 mM, respectively; (Knecht et al.,
2000; Gonzalez-Aragon et al., 2007)]. Together, these findings
suggest that the overall level of NQO1 activity during
early zebrafish development is low, in contrast with that
of DHODH. Consistently, dicoumarol failed to modulate
chronic toxicity of menadione or b-lapachone suggesting
they are not being significantly detoxified or bioactivated by
NQO1. Still, specific organs like the heart may exhibit higher
NQO1 activity, as addressed below.
Cardiovascular abnormalities and ubiquinone. Mitochondrial
respiratory chain dysfunction and ubiquinone deficiency dis-
orders are frequently associated with cardiovascular manifes-
tations (Berardo et al., 2011). Consistently, we show that
mitochondrial inhibitors induce cardiac oedema associated
with bradycardia and arrhythmia in zebrafish. Interestingly,
we identified an unusual cardiovascular phenotype for
4NB and atovaquone, consisting in focal bleeding and
necrosis, with pronounced cardiac oedema but normal heart
rate. Meaningfully, 4NB inhibits ubiquinone biosynthesis
(Forsman et al., 2010), atovaquone was suggested to cause
feedback inhibition of ubiquinone biosynthesis (Kaneshiro
et al., 2000), and the ubiquinone precursor 4HB reduces
atovaquone but not myxothiazol or antimycin toxicity.
Therefore, data suggests that this unusual cardiovascular phe-
notype reflects ubiquinone deficiency, and may thus assist
future study of related disorders in zebrafish.
In vivo testing of quinone analogues
Quinone analogues as research tools and chemotherapeutics.
Quinone analogues are widespread in nature, playing key
roles in electron transport chains and in interspecies chemi-
cal warfare. Their ability to interfere with biological processes
stems from redox properties, and has promoted their use as
research tools and as putative anticancer or antiparasitic
drugs (O’Brien, 1991).
Menadione is a research tool for inducing oxidative stress,
increasing mitochondria superoxide by redox cycling
(Johnson-Cadwell et al., 2007). While sometimes used as pre-
cursor for vitamin K, menadione may induce haemolysis
in patients lacking glucose-6-phosphate dehydrogenase
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(Roberts-Harewood, 2009). Here, we report that menadione
causes hypochromic anaemia in zebrafish when present
between 24 and 32 hpf, following primitive erythropoiesis
(Chen and Zon, 2009), but not when present for longer sub-
sequent periods. Hence, instead of acute haemolysis, data
suggests that menadione impairs zebrafish haematopoiesis,
possibly by depolarizing mitochondria via redox-cycling or
complex I inhibition (Dong et al., 2009) and disturbing mem-
brane potential-dependent biosynthesis of the iron-sulfur
cluster haem (Figure 8D) (Ye and Rouault, 2010). Thus, we
suggest that menadione may be a useful research tool for
studying erythropoiesis and its mitochondrial dependence in
zebrafish.
Lapachol and b-lapachone are putative anticancer lead
compounds, with their presence in plant extracts (e.g. Tabe-
buia impetiginosa) being associated with cytotoxicity against
multiple cell lines (Gomez Castellanos et al., 2009). Similar
reasoning applies to diospyrin, diosquinone, juglone and
plumbagin. Here, we show that the LC50 of these quinone
analogues in developing zebrafish is similar or even smaller
than reported for cancer cells. Considering the similarities
between cellular divisions in a developing embryo and in
cancer cells, results suggest caution in interpreting data from
zebrafish embryos whilst testing for selective anticancer
toxicity.
Atovaquone is used therapeutically against Pl. falciparum
malaria and Pn. jiroveci pneumonia. Selective toxicity for
parasites versus humans is achieved by structural differences
in atovaquone’s target – the cytochrome b Qo site in complex
III (Kessl et al., 2003). Here, we report a high amino acid
homology of zebrafish, mice and humans at the Qo and Qi
sites, confirming predicted functional differences by compar-
ing LC50 of atovaquone, myxothiazol and antimycin with
that reported for parasites. Together, data supports using
in vivo zebrafish assays for comparative toxicity of
mitochondria-targeted quinone analogues, namely in anti-
malaric drug research.
Ubiquinone analogues and treatment of mitochondrial dysfunc-
tion. Ubiquinone analogues are among the few specific
therapeutic options for mitochondrial diseases (Napolitano
et al., 2000). Idebenone improved cardiac function in Frie-
drich ataxia (Rustin et al., 1999), with higher doses required
for improving neurological function (Di Prospero et al.,
2007). Idebenone effects have been ascribed to antioxidant
properties (Geromel et al., 2002). Further, idebenone can
mimic ubiquinone, transferring to complex III the electrons
received from mitochondrial dehydrogenases, thus promot-
ing mitochondrial ATP production (Brière et al., 2004).
Although ubiquinone analogues have failed to rescue ubiq-
uinone deficient cells (Lopez et al., 2010), there are also evi-
dences that idebenone’s ability to rescue ATP levels correlates
with NQO1 activity (Haefeli et al., 2011), promoting ide-
benone reduction and subsequent complex III feeding.
Current support for this hypothesis stems from in vitro evi-
dence, using cells or isolated mitochondria and predictive
parameters such as ATP levels and oxygen consumption.
Here, we explore this hypothesis in vivo, using zebrafish and
cardiovascular parameters, testing the ability of ubiquinone
analogues to prevent/delay cardiac insufficiency following
induced mitochondrial dysfunction.Fi
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Idebenone and decylubiquinone significantly delayed
cardiac insufficiency and asystole evoked by acute rotenone
exposure. However, both drugs were ineffective against
chronic rotenone exposure, as ubiquinone analogues clearly
cannot sustainably protect from chronic multi-organ toxic-
ity. The mechanisms of cardioprotection by idebenone and
decylubiquinone in our zebrafish model are more likely
related to increased ATP production efficiency than to anti-
oxidant or reactive oxygen species (ROS) scavenging prop-
erties. Indeed, these ubiquinone analogues were without
effect against both acute and chronic complex III inhibi-
tion, particularly with antimycin that is also an inducer of
mitochondrial ROS production (Chandel et al., 2000). Thus,
transient cardiac protection from acute rotenone exposure
in zebrafish might be explained by higher NQO1 activity in
the heart [as in mammals: (Palming et al., 2007; Zhu and
Li, 2012)], allowing enhanced local ubiquinone analogue
reduction (Haefeli et al., 2011; Giorgio et al., 2012), and
consequently more feeding of complex III and ATP produc-
tion in the heart.
In future studies of mitochondrial dysfunction in
zebrafish, it would be valuable to further explore ATP/ADP
ratios as well as ROS production in this model organism.
Significantly, Mendelsohn et al. (2008) have monitored AMP/
ATP by HPLC and total ATP by luciferase assays in zebrafish.
Also, Niethammer et al. (2009) have successfully used a
genetically encoded H2O2 sensor in zebrafish.
Concluding remarks
In summary, the present work supports zebrafish for study-
ing mitochondrial dysfunction and testing mitochondria-
targeted treatments. Our reported developmental and
cardiovascular phenotypes should assist further research on
mitochondrial diseases in this model organism. The present
data, on mitochondrial sequence analysis and atovaquone
effects, highlights zebrafish’s potential for the in vivo differ-
ential toxicity screening of mitochondria-targeted antipara-
sitic drugs. Further, our in vivo assay identifying a delay of
cardiac failure by idebenone and decylubiquinone may
assist comparisons of other ubiquinone analogues, currently
being developed as mitochondria-targeted drugs. Data on
other quinone analogues (especially menadione) should
assist their use as research tools. Lastly, our data showing a
relatively low dependence of young zebrafish on mitochon-
drial complex I/II for ATP production should help inter-
pret phenotypes of disease models linked to complex I/II
inhibition.
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